🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07759362
Recruiting Phase 3

Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)

NCT07759362 · tracked via the Priya Life Science USA tracker
Sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 3
Started
2026-08-11
Last updated
2026-09-14

Condition(s) studied

Flexible HammertoeSemi-flexible Hammertoe

Investigational drug(s) / intervention(s)

KN3835Placebo

KN3835: Participants will receive KN3835.

Placebo: Participants will receive placebo matching to KN3835.

Study summary

The primary purpose of this study is to assess the efficacy, safety, and tolerability of KN3835 compared to placebo in the treatment of flexible/semi-flexible HMT.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Key Inclusion Criteria: * Has no significant medical history or examination findings related to the foot to be treated, which in the investigator's opinion, would make the participant unsuitable for study intervention administration or study required evaluations. * If female, be of non-childbearing potential or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective contraception when with a male partner for the duration of the study and for 28 days after treatment. * Be willing and able to comply with all protocol required visits and assessments. Key Exclusion Criteria: * Has any musculoskeletal, neurosensory, other neurological or related disorder that affects the participant's use of his/her feet and/or would impair his/her completion of study assessments as determined by the investigator either due to the disorder or due to pain. * Has any significant medical condition(s), which in the investigator's opinion would make the participant unsuitable for enrollment in the study. * Has previously participated in clinical studies of KN3835 for plantar fasciitis, plantar fibromatosis, or HMT. Note: Other inclusion/exclusion criteria may apply.

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Keenova Site-009 Corona California Recruiting
Keenova Site-008 Tarzana California Recruiting
Keenova Site-004 Pinellas Park Florida Recruiting
Keenova Site-007 Sweetwater Florida Recruiting
Keenova Site-003 Bedford Texas Recruiting
Keenova Site-002 McAllen Texas Recruiting
Keenova Site-006 Salt Lake City Utah Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07759362 on ClinicalTrials.gov ↗ ← All trials in the USA